Roche, billionaire-backed biotech partner on hep C drug in China

Roche ($RHHBY) and the biotech startup Ascletis have joined forces to advance Roche's experimental drug danoprevir for hepatitis C virus in the Chinese market. As Reuters reports, the deal comes as Roche sees a decline in sales of its injected interferon therapy Pegasys for hepatitis C, which many researchers want to treat with all-oral drugs. Under the new pact, Ascletis--which launched in 2011 with backing from Chinese real estate mogul Jinxing Qi--is expected to fund development and manufacturing of the drug in China and receive royalties and payments from the Swiss drug giant on potential sales of the protease inhibitor. Article

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.